|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||1.9575 - 2.1399|
|52-week range||1.5400 - 7.7600|
|Beta (5Y monthly)||1.12|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.00|
Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals Inc., ("Medexus" or the "Company") (TSX: MDP), and his team joined Daniel Lubienietzky, Manager, Life Sciences, TMX Group, to celebrate the Company's new listing on Toronto Stock Exchange and open the market.
Sunquest provides various interoperable products and services that work with each other to improve lab efficiency and results accuracyLONDON, March 2, 2021 /CNW/ -- Based on its recent analysis of the North American laboratory information management systems (LIMS) market for molecular and genetic diagnostics, Frost & Sullivan recognizes Sunquest Information Systems with the 2021 North America Company of the Year Award. Sunquest's comprehensive portfolio of products and services improves operational efficiency, enhances patient care, and lowers healthcare organizations' costs across the spectrum.
3, 2021 /CNW/ - Trading resumes in: Company: Medexus Pharmaceuticals Inc.TSX-Venture Symbol: MDPAll Issues: YesResumption (ET): 11:00 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.